Company intelligence / Profile preview

Ayala Pharmaceuticals, Inc.

Monmouth Junction, New Jersey, United Statesayalapharma.com ↗

Ownership: Public · ADXS
Employees: ~20
Development stage: Phase 3

Overview

Ayala Pharmaceuticals has completed enrollment in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors with 156 patients enrolled. AL102 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA. The company is also developing aspacytarabine (BST-236) for first line treatment in unfit acute myeloid leukemia (AML).

Therapeutic areas: Oncology
Modalities: Small molecule therapeuticsGamma secretase inhibitors
Industry: Biotech

Drug pipeline

4 assets

osugacestat

3 more assets in the full pipeline.

Request access →

Partnerships

Novartis (WVT078 combination trial)Biosight (merged in 2023)

Financials

Market cap: $25.7M
Total revenue: $0
Enterprise value: $29.1M

Beyond the preview

Go deeper on Ayala Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ayala Pharmaceuticals, Inc..

Explore the full profile